|
Article Summary
|
|
|
Laas K et al. - Etanercept can be suggested in RA patients when infliximab has failed or discontinued for other reasons. Methods- Disease activity was measured in RA pts (n=49) after switching from infliximab to etanercept
- Reasons for infliximab discontinuation were: 42% for failure to respond by >ACR 50% criteria; 12% for AEs; 46% for non-medical reasons
- Clinical outcome after the switch was compared between the groups according to the reason of infliximab discontinuation
- Disease activity was measured with DAS28
Results- In pts in the non-medical reasons group, the disease activity was suppressed effectively both during infliximab and etanercept
- One-year drug survival of etanercept in this group was the highest of 77% among the 3 groups
- In pts in the infliximab failure and AE groups, DAS28 values improved during etanercept therapy
- The 1-yr drug survival of etanercept was 43% and 50% respectively
- For RA pts who discontinued taking infliximab because of non-medical reasons experienced similar treatment efficacy during both biological agents
- The treatment with etanercept provided sufficient disease control also for pts with infliximab failure or AE
 |
| Sponsor |
--- CLINICAL PHARMACOLOGY TOP ARTICLES ---
Receive free subspecialty "5-minute updates" via email
|
 |
|
| Read a Different Specialty |
 |
|
|
|
|
| Profession Index |
|
|
|
|
|
|
 |
| Sponsor |
|
